Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Open Access

Figure 5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSamantha I. LiangParker Institute for Cancer ImmunotherapyZQZoe QuandtUniversity of California, San FranciscoSWSara WienkeGuardant (United States)

Discussion

Loading...

Member takes

Implication

Real-world analysis shows ctDNA tumor fraction correlates with outcomes in cancer patients, suggesting new monitoring strategies.

Key Points

  • Patients with a complete response had extended rwPFS of 15 months, showing possible benefits of monitoring tumor fraction.
  • In the study, patients with NSCLC had rwPFS of 13.77 months, indicating meaningful progression-free survival times from ctDNA monitoring.
  • Observational analysis across multiple cancer types revealed significant differences in tumor fraction, aligning with patient outcomes.
  • These findings suggest ctDNA monitoring may provide vital insights for enhancing cancer treatment success.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af750c7567bf4f94feddd2https://doi.org/10.1158/2767-9764.29948099
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  2. 2Supplementary Figure S3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  3. 3Figure 4 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  4. 4Data from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  5. 5Figure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025